Harnessing the power of genomic sequencing augments diagnosis and treatment of lymphoid cancer


A new study has established that hybrid-capture sequencing is the method of choice for sequencing ‘actionable’ gene mutations across the most common forms of lymphoid cancer. Due to its applicability in routinely acquired formalin-fixed, paraffin-embedded tissues, this assay can be implemented by clinical laboratories into routine diagnostic workflows. It reliably identifies potentially actionable gene mutations in 91 percent of patients, bringing the benefits of precision diagnosis and individualized therapy to patients with lymphoid cancer.